1983 - 1989 B.M., Beijing Medical University

1989 - 1997 Assistant Researcher, Pediatric Institute, Beijing Children's Hospital

1998 - 2004 Ph.D. State University of New York at Buffalo

2004 - 2010 Postdoctoral fellow, National Institute of Health (LVD/NIAID/NIH)

2010 - Associate Prof., Professor, Principal Investigator, Institute of Biophysics, CAS

1. Study of host immune response to virus infection, viral pathogenic mechanism, and virus-associated malignancy.

2. Development of novel preventive and therapeutic vaccines against viral infections and immune based anti-cancer drugs.

1. Diyuan Xue, Benjamin Moon, Jing Liao, Jingya Guo, Zhuangzhi Zou, Yanfei Han, Shuaishuai Cao, Yang Wang, Yang-Xin Fu*,Hua Peng*. A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors.Sci Immunol. 2022 January 7 7;6(59)eabi6899.

2. Shiyu Sun, Xi Chen, Jingjing Lin, Junwen Ai, Jiaming Yang, Zhenxiang Hu, Yang-Xin Fu*,Hua Peng*. Broad neutralization against SARS-CoV-2 variants induced by a next-generation protein vaccine V-01.Cell Discov. 2021 Nov 30;7(1):114.

3. Jingya Guo, Yong Liang, Diyuan Xue, Jiao Shen, Yueqi Cai, Jiankun Zhu, Yang-Xin Fu*,Hua Peng*. Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity.Cell Res. 2021 Nov;31(11):1190-1198.

4. Sunshiyu Sun, Yueqi Cai, Tian-Zhang Song, Yang Pu, Lin Cheng, Hairong Xu, Chaoyang Meng Yifan Lin, Haibin Huang, Fang Zhao, Jing Sun, Silin Zhang, Yu Gao, Jian-Bao Han, Xiao-Li Feng, Dan-Dan Yu, Haidong Tang, Jincun Zhao, Zheng Zhang, Jiaming Yang, Zhenxiang Hu, Yang-Xin Fu*, Yong-Tang Zheng*,Hua Peng*. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2.Cell Res. 2021 Sep;31(9):1011-1023.

5. Shu YJ, He JF, Pei RJ, He P, Huang ZH, Chen SM, Ou ZQ, Deng JL, Zeng PY, Zhou J, Min YQ, Deng F,Peng H, Zhang Z, Wang B, Xu ZH, Guan WX, Hu ZY, Zhang JK. Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial.Chin Med J (Engl). 2021 Jul 22;134(16):1967-1976.

6. Zhang J, Hu Z, He J, Liao Y, Li Y, Pei R, Fang X, Zeng P, Fan R, Ou Z, Deng J, Zhou J, Guan W, Min Y, Deng F,Peng H, Zhang Z, Feng C, Xin B. Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial.Emerg Microbes Infect. 2021 Dec;10(1):1589-1597.

7. Xue D, Hsu E, Fu YX,Peng H*. Next-generation cytokines for cancer immunotherapy.Antib Ther. 2021 Jun 25;4(2):123-133.

8.Peng H, Fu YX., The Inhibitory PVRL1/PVR/TIGIT Axis in Immune Therapy for Hepatocellular Carcinoma.Gastroenterology. 2020 Jun 20:S0016-5085(20)34822-8.

9. Sisi Deng, Zhichen Sun, Jian Qiao, Yong Liang, Longchao Liu, Chunbo Dong, Aijun Shen, Yang Wang, Hong Tang*, Yang-Xin Fu*, andHua Peng*. Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells.JCI Insight. 2020;5(7):e132000.

10. Wang W, Zhou X, Bian Y, Wang S, Chai Q, Guo Z, Wang Z, Zhu P,Peng H, Yan X, Li W, Fu YX, Zhu M., Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B.Nat Nanotechnol. 2020 May;15(5):406-416.

11. Zhichen Sun, Zhenhua Ren, Kaiting Yang, Shuaishuai Cao, Sisi Deng, Lily Xu, Yong Liang, Jingya Guo, Yingjie Bian, Hairong Xu, Jiyun Shi, Fan Wang, Yang-Xin Fu*, andHua Peng*. A next generation tumor-targeting IL-2 preferentially promotes tumor infiltrating CD8+ T cells response and effective tumor control.Nat Commun. 2019 Aug 28;10(1):3874.

12. Sun Z, Fu YX,Peng H*. Targeting tumor cells with antibodies enhances anti-tumor immunity.Biophys Rep. 2018;4(5):243-253.

13. Yong Liang, Haidong Tang, Jingya Guo, Xiangyan Qiu, Zhenhua Ren, Yingjie Bian, Zhichen Sun, Haidong Dong,Hua Peng*, Yang-Xin Fu*. Targeting type I interferon tumor entry by anti-PD-L1 creates feedforward antitumor responses to overcome innate and adaptive resistance.Nat Commun. 2018 Nov 2;9(1):4586.

14. Yang K, Liang Y, Sun Z, Liu L, Liao J, Xu H, Zhu M, Fu YX*,Peng H*. T cell-derived lymphotoxin limits Th1 response during HSV-1 infection.Sci Rep. 2018 Dec 7;8(1): 17727.

15. Liu X, Liu L, Ren Z, Yang K, Xu H, Luan Y, Fu K, Guo J,Peng H, Zhu M, Fu YX. Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion.Cell Rep. 2018 Aug 21;24(8):2101-2111.

16. Yang K, Liang Y, Sun Z, Xue D, Xu H, Zhu M, Fu YX*,Peng H*. J Virol. T cell-derived Lymphotoxin is Essential for anti-HSV-1 Humoral Immune Response.J Virol. 2018 Jun 29;92(14). pii: e00428-18.

17. Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, Liu X, Harrington SM, Guo J, Xin Y, Xiong Y, Nham K, Silvers W, Hao G, Sun X, Chen M, Hannan R, Qiao J, Dong H*,Peng H*, Fu YX.*. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.J Clin Invest. 2018 Feb 1;128 (2):580-588.

18. Bian Y, Zhang Z, Sun Z, Zhao J, Zhu D, Wang Y, Fu S, Guo J, Liu L, Su L, Wang FS, Fu YX*,Peng H*. Vaccines Targeting PreS1 Domain Overcome Immune Tolerance in HBV Carrier Mice.Hepatology. 2017 Oct;66(4):1067-1082.

19. Jing Liao, Yan Luan, Zhenhua Ren, Xiaojuan Liu, Hairong Xu, Zhichen Sun, Kaiting Yang,Hua Peng*, and Yang-Xin Fu*. Converting lymphoma cells into potent antigen presenting cells for interferon-induced tumor regression.Cancer Immunol Res. 2017 Jul;5(7):560-570.

20. Yong Liang andHua Peng*. LIGHTing tumor up for checkpoint blockade,Oncotarget. 2016 Aug 2;7(31):48857-48858.

21. Ren Z,Peng H, Fu YX. PD-1 Shapes B Cells as Evildoers in the Tumor Microenvironment.Cancer Discov. 2016 May; 6(5):477-8.

22. Ren Z, Guo J, Liao J, Luan Y, Liu Z, Sun Z, Liu X, Liang Y,Peng H*, Fu YX*. CTLA-4 limits anti-CD20-mediated tumor regression.Clin Cancer Res. 2017 Jan 1;23(1):193-203.

23. Danming Zhu, Longchao Liu, Junming He, Dan Yang, Yingjie Bian, Zhichen Sun, Lishan Su, Liguo Zhang,Hua Peng*, and Yang-Xin Fu*. Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination.J Immunol. 2016 Apr 1;196 (7):3079-87.

24. Liang Y,Peng H*. STING-cytosolic DNA sensing: the backbone for an effective tumor radiation therapy.Ann Transl Med. 2016 Feb;4(3):60.

25. Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, Xu H,Peng H, Fu YX, Xu MM. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors.Nat Med. 2015 Oct;21(10):1209-15.

26. Yong Liang, Kaiting Yang, Jingya Guo, Joanna Wroblewska, Yang-Xin Fu andHua Peng. (2015) Innate lymphotoxin receptor mediated signaling promotes HSV-1 associated neuroinflammation and viral replication,Sci Rep., 2015 May 20;5:10406.

27. Yang D, Liu L, Zhu D,Peng H, Su L, Fu YX, Zhang L., A mouse model for HBV immunotolerance and immunotherapy.Cell Mol Immunol. 2014 Jan;11(1):71-8

28. Kris White,Hua Peng, John Hay, and William T. Ruyechan. (2010) Role of the IE62 consensus binding site in transactivation by the varicella zoster virus IE62 protein.J. Virol. Apr. 84(8): 3767-79.

29.Hua Peng, Mauricio L. Nogueira, Jodi L. Vogel, and Thomas M. Kristie. (2010) The transcriptional coactivator HCF-1 couples the histone chaperone Asf1b to HSV-1 DNA replication components.PNAS. 2010 Feb 9,107(6): 2461-2466.

30. Yu Liang, Jodi L. Vogel, Aarthi Narayanan,Hua Peng, and Thomas M. Kristie. Inhibition of the histone demethylase LSD1 blocks α-herpesvirus lytic replication and reactivation from latency.Nat. Med. 2009 Nov;15(11):1312-7.

31. Min Yang,Hua Peng, John Hay, and William T. Ruyechan. (2006) Promoter Activation by the Varicella-Zoster Virus Major Transactivator IE62 and the Cellular Transcription Factor USF.J. Virol. 80: 7339-7353.

32.Hua Peng, Hongying He, John Hay, and William T. Ruyechan (2003) Interaction between the varicella zoster virus IE62 Major transactivator and cellular transcription factor Sp1.J. Biol. Chem. 278: 38068-38075.

(From Hua Peng, February 16, 2022)